A 83-01 (CAS: 909910-43-6)
|
SKU-Pack Size | Availability | Size | Price | |
EBC51012-2MG | In Stock | 2mg | ¥390.00 | |
EBC51012-5MG | In Stock | 5mg | ¥590.00 | |
EBC51012-10MG | In Stock | 10mg | ¥1390.00 | |
EBC51012-25MG | In Stock | 25mg | ¥2190.00 | |
EBC51012-50MG | In Stock | 50mg | ¥3790.00 |
Please Select The Country You Are In To Find Your Local Distributor. |
北京美瑞克生物科技有限公司 | Phone: +86 010-62890160 / 13691184142(微信同号) | |
2 / F, 128 malianwa North Road, Haidian District, | E-mail: mrkbio@163.com | |
China | Beijing China | Website: www.mrkbio.com |
Product Information | |||||||||||||||||||||
Synonym(s) | ALK5 Inhibitor IV | ||||||||||||||||||||
Chemical Name | 3-(6-Methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide | ||||||||||||||||||||
Application | A 83-01 is a small-molecule inhibitor of activin receptorlike kinase (ALK)-5 | ||||||||||||||||||||
CAS Number | 909910-43-6 | ||||||||||||||||||||
Purity | ≥98.0% | ||||||||||||||||||||
Molecular Weight | 421.52 | ||||||||||||||||||||
Molecular Formula | C₂₅H₁₉N₅S | ||||||||||||||||||||
SMILES | CC1=CC=CC(=N1)C2=NN(C=C2C3=CC=NC4=CC=CC=C34)C(=S)NC5=CC=CC=C5 | ||||||||||||||||||||
Target & IC50 | ALK5 kinase: IC50 = 12 nM ALK4: IC50 = 45 nM ALK7: IC50 = 7.5 nM |
||||||||||||||||||||
Solubility | DMSO: 10mg/mL (23.72 mM) | ||||||||||||||||||||
Preparing Stock Solutions |
|
||||||||||||||||||||
Shipping | Gel Pack | ||||||||||||||||||||
Storage | Store at -20°C | ||||||||||||||||||||
Research Use | For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use. |
Product Description | |
A 83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values are 12, 45 and 7.5 nM respectively). A 83-01 blocks phosphorylation of Smad2 and inhibits TGF-β-induced epithelial-to-mesenchymal transition. A 83-01 lonly weakly inhibits ALK-1, -2, -3, -6 and MAPK activity. A 83-01 is more potent than SB 431542. Fibroblasts can be reprogrammed by A 83-01 into alternative lineages. |
Specific Protocols | |